Welcome, Guest. Please login or register.
July 31, 2021, 08:01:49 am

Login with username, password and session length


Members
Stats
  • Total Posts: 760814
  • Total Topics: 64558
  • Online Today: 3780
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 1
Guests: 3185
Total: 3186

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Islatravir Shows Promise for Once-Monthly Oral PrEP  (Read 1106 times)

0 Members and 1 Guest are viewing this topic.

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 17,420
  • Twitter @JimAllenDublin
    • HIV Lessons
Islatravir Shows Promise for Once-Monthly Oral PrEP
« on: January 26, 2021, 02:01:59 pm »
Cool. Will be interesting to see further results over the next for years for the PrEP & Treatment combinations.

In Full: https://www.poz.com/article/islatravir-shows-promise-oncemonthly-oral-prep

In Brief:

Quote
At HIVR4P, Sharon Hillier, PhD, of the University of Pittsburgh Magee-Womens Research Institute, presented early findings from an ongoing Phase IIa trial of once-monthly islatravir for PrEP.

This randomized, double-blind study is evaluating the safety, tolerability and pharmacokinetics of islatravir in adults at low risk for HIV. Participants were randomly allocated to receive six doses of 60 or 120 milligrams of islatravir or a placebo, all administered as tablets once monthly.

The study completed enrollment with 242 participants in November 2020. Hillier reported results from an interim analysis of 192 people who were randomized and started taking the tablets. About two thirds were women, 64% were white, 30% were Black and 16% were Latino; the median age was 32 years.

For the pharmacokinetic analysis, islatravir levels were measured in blood plasma, peripheral blood mononuclear cells (T cells and other immune cells) and biopsies of rectal, cervical and vaginal tissue.

People taking either the 60 mg or 120 mg tablets had trough levels of the active form of islatravir in their peripheral blood cells—meaning the lowest level between doses—that were well above the thresholds that provided full protection in monkeys and antiviral activity in people with HIV in a treatment study.

A preliminary analysis of tissue biopsies suggested that islatravir was rapidly distributed and reached adequate levels that were sustained between doses.

What’s more, both doses of islatravir were well tolerated. Most adverse events were mild or moderate and resolved on their own. The most common adverse events were headache, diarrhea and nausea. There were no serious adverse events and no deaths, and only two people stopped treatment due to potentially drug-related adverse events.

Although these findings suggest that a lower dose or longer dosing interval would still work, Hillier explained that a conservative dosing regimen was chosen to allow for some degree of forgiveness—for example, if a person takes a pill late or even misses a dose. The 60 mg dose was selected for future clinical trials.

Last November, Merck and the Bill & Melinda Gates Foundation launched a Phase III trial called IMPOWER 22 that will evaluate the safety and efficacy of islatravir PrEP in cisgender women and adolescent girls at high risk for HIV in sub-Saharan Africa. Approximately 4,500 participants will be randomly assigned to receive once-monthly oral islatravir or once-daily Truvada (tenofovir disoproxil fumarate/emtricitabine).

Another planned trial, IMPOWER-024, will enroll cisgender men and transgender women who have sex with men in countries around the world. They will be randomized to receive once-monthly islatravir or once-daily Truvada or Descovy (tenofovir disoproxil fumarate/alafenamide), the latter of which is not yet approved for people exposed to HIV via vaginal sex.

An implantable formulation of islatravir is also being studied for PrEP. About the size of a matchstick, the implant releases a small amount of the drug over time, similar to implants used for long-acting contraception. An early study of HIV-negative volunteers showed that the implant delivered protective concentrations of the drug for more than a year.

On the treatment front, findings presented in October showed that a combination of once-daily islatravir plus Pifeltro (doravirine) demonstrated good efficacy in a Phase IIb trial. After 96 weeks, 90% of people treated with the selected dose of islatravir plus Pifeltro had an undetectable viral load. But thanks to its long half-life, islatravir has the potential to be taken less often. Merck plans to evaluate islatravir plus its experimental non-nucleoside reverse transcriptase inhibitor MK-8507 as a once-weekly treatment regimen.

If the Phase III trials of oral islatravir PrEP go as planned, Hillier said she hoped it might be available by 2024
.
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

 


Terms of Membership for these forums
 

© 2021 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.